Lilly, AbCellera tout antibody combo To view this email as a web page,
click here Startup collaborates with NewYork-Presbyterian, Vanderbilt to test video game therapy for COVID 'brain fog' 'Very stressed' Serum Institute asks government for $400M vaccine production boost Lilly, AbCellera tout COVID-19 antibody combo potential as it loses strength against variants Hologic inks its largest COVID-powered acquisition yet with $795M for test maker Mobidiag CMS proposes 2% pay bump for rehab, psychiatric facilities COVID-19 tracker: BeiGene's Brukinsa comes up short in trial Bristol Myers Squibb's regulatory missteps on Breyanzi can't all be blamed on COVID: analyst CytoDyn's chief scientific officer Rahman quietly exits amid leronlimab limbo Featured Story | By Heather Landi Boston-based Akili Interactive is collaborating with Weill Cornell Medicine, NewYork-Presbyterian Hospital and Vanderbilt University Medical Center to evaluate the company's digital therapeutic, which got a green light from the FDA last summer as a treatment for ADHD. read more |
| |
|---|
|
Top Stories By Kevin Dunleavy With pressure mounting domestically and abroad for COVID-19 vaccine supplies, the Serum Institute of India is asking its country for assistance in boosting production of the AstraZeneca shot. read more By Angus Liu The feds stopped distributing Eli Lilly's and AbCellera's COVID drug bamlanivimab as a monotherapy, out of concern that it may not be effective against new coronavirus variants. Now the companies have new findings that they believe provide support for the drug to be used with another antibody to protect against those variants. read more By Conor Hale After reaping a windfall from COVID-19 diagnostic demand, Hologic’s spending spree continues with its largest acquisition yet: It’s claimed Mobidiag, the Finnish-French molecular test maker, with a $795 million deal. read more By Robert King CMS is proposing slight pay bumps for both rehab and psychiatric facilities for the 2022 fiscal year that starts in October, and has new requirements to track COVID-19 vaccinations. read more By Kevin Dunleavy,Fraiser Kansteiner,Eric Sagonowsky BeiGene's phase 2 trial of Brukinsa on COVID patients requiring oxygen failed to reach its endpoints. The Serum Institute of India has asked its government for a $400 million grant to bump up production of AstraZeneca COVID-19 vaccines. The FDA has approved an at-home COVID-19 antibody test for the first time. And more headlines. read more By Eric Sagonowsky Bristol Myers Squibb’s February approval for CAR-T lymphoma med Breyanzi came after multiple delays that ended up costing investors in a big way. FDA documents now offer clues about what went wrong, a biotech analyst writes. read more By Ben Adams CytoDyn has lost its chief scientific officer Mahboob Rahman, M.D., Ph.D., just six months into his tenure at the biotech. read more |
|
